Dr. Xudong Qu 瞿旭东
Chief Physician
Department of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Interventional and ablation therapies for liver, lung, and gastrointestinal tumors; radioactive seed and stent treatment for portal vein tumor thrombus; interventional treatment for biliary obstruction, uterine fibroids, adenomyosis, and peripheral vascular diseases.
Dr. Qu holds a medical doctorate and serves as a Chief Physician.
Name order: in Chinese the family name comes first (Qu Xudong). Papers usually list the name as Xudong Qu or Qu X.
Selected publications
56 papers on PubMed matched by name and affiliation; 15 as first or senior author since 2016. Most recent first- or senior-author papers:
- Gut Microbes, 2026 (senior author): Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy. PubMed 42212684
- Int J Cancer, 2026 (senior author): Efficacy and safety of bronchial arterial infusion chemotherapy combined with transarterial chemoembolization and systemic therapy in hepatocellular carcinoma patients with lung metastases. PubMed 41741935
- Mol Cancer, 2026 (senior author): Ferroptosis as a therapeutic target in cancer: mechanisms, immune interactions, and emerging strategies. PubMed 41957797
- J Hepatocell Carcinoma, 2026 (senior author): A Case of Microwave Ablation Activating Immune Response in Pulmonary Metastases from Hepatocellular Carcinoma. PubMed 41868258
- BMC Cancer, 2026 (senior author): Clinical efficacy of HAIC combined with TACE in patients with unresectable intrahepatic cholangiocarcinoma. PubMed 41814242
- Int J Cancer, 2026 (senior author): Immune checkpoint inhibitor-induced vitiligo: A large-scale real world pharmacovigilance study. PubMed 40966008
- Research (Wash D C), 2026 (senior author): Transarterial Chemoembolization Modulates the Exosomal miR-32-5p/cGAS-STING Axis Mediated Macrophage Ferroptosis, Triggers Immune Remodeling, and Enhances Anti-PD-1/L1 Efficacy in HCC. PubMed 41608526
- CNS Neurosci Ther, 2026 (senior author): Pharmacovigilance Insights Into Immune Checkpoint Inhibitor-Induced Risk of Paraneoplastic Syndrome: A Large-Scale Real World Study. PubMed 41562147
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion